Phase 3 Stroke Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 40 years or older
• People who have had a mild ischemic stroke (a stroke caused by a blocked blood vessel, with only minor symptoms) or a transient ischemic attack (TIA, sometimes called a "mini-stroke") that is considered moderate-to-high risk for a future stroke
• People whose stroke or TIA is linked to a significant narrowing (50% or more) of an artery inside the brain, confirmed by a specific type of brain scan (MRA, CTA, or DSA)
• People who can begin the study treatment within 24 hours of when their symptoms first started (or when they were last seen to be well)
• People who have signed a consent form agreeing to take part

Who may not be able to join:

• People whose brain scan shows a brain tumour, abnormal blood vessel growth, abscess, or other major non-stroke brain condition (such as multiple sclerosis)
• People for whom the degree of artery narrowing inside the brain cannot be measured before the study begins
• People whose only symptoms are numbness, visual changes, or dizziness/vertigo, with no sign of a stroke on brain scans
• People whose minor stroke or TIA was caused by a previous medical procedure such as surgery or an artery-widening procedure
• People who had significant physical disability before this stroke or TIA (confirm with trial site)
• People who have a known allergy to the study drug (tirofiban)
• People with severely reduced kidney or liver function based on blood test results
• People with severe heart failure
• People with a history of bleeding disorders or serious bleeding episodes
• People with a history of abnormally low platelet or white blood cell counts, or a history of blood or liver problems caused by medication
• People whose current blood test shows very low white blood cell or platelet counts
• People who have already received tirofiban for this current episode
• People with a very low red blood cell level (low haematocrit)
• People who have a clear medical reason to be on blood-thinning (anticoagulant) medication, such as atrial fibrillation, artificial heart valves, or suspected heart infection
• People with a history of bleeding inside the brain or a condition called amyloid angiopathy
• People with a history of an aneurysm (a bulge in a blood vessel) anywhere in the body
• People with a history of asthma or chronic obstructive pulmonary disease (COPD)
• People considered at high risk for a dangerously slow heart rate, without a pacemaker in place
• People for whom a procedure to open a blocked artery (such as angioplasty) is planned within the next 3 months
• People who have surgery or another procedure planned that would require stopping the study medication
• People with a serious non-heart-related illness where life expectancy is less than 3 months
• People who, due to a mental health, cognitive, or emotional condition, are unable to understand or follow the study procedures
• People who have received heparin or oral blood-thinning medication within the 10 days before joining the study
• People who have received clot-dissolving medication given into a vein (such as rtPA) or had a mechanical clot removal procedure within the 24 hours before joining the study
• People whose baseline brain CT scan shows a large area of damage (greater than half of the middle cerebral artery territory)
• People who have had a gastrointestinal bleed within the past 3 months, or major surgery within the past 30 days
• People with a confirmed or suspected diagnosis of acute coronary syndrome (a sudden serious heart condition)
• People who have taken part in another clinical trial using an experimental product within the past 30 days
• People who are currently receiving any other experimental drug or using an experimental device
• People who are pregnant, trying to become pregnant, or of childbearing potential and not using contraception

Important: Always verify eligibility with the trial site directly before applying.